Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Documenti analoghi

• Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
  di: Shen, Lin, et al.
  Pubblicazione: (2020)
• Phase I, multicenter, open‐label, dose‐escalation study of sonidegib in Asian patients with advanced solid tumors
  di: Minami, Hironobu, et al.
  Pubblicazione: (2016)
• A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors
  di: Rodon, Jordi, et al.
  Pubblicazione: (2018)
• An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
  di: Taylor, Kirsty, et al.
  Pubblicazione: (2020)
• A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
  di: Sharman, Jeffrey P., et al.
  Pubblicazione: (2019)